Targeted Radiotherapies Actinium specializes in targeted radiotherapies for solid tumors and hematologic cancers, offering a compelling value proposition for oncology partners seeking differentiated radioconjugates with tumor-specific activity.

Pipeline Collaboration Recent and ongoing collaborations, including Actimab-A with the NCI and the Iomab/B conditioning programs, suggest opportunities for co-development, research partnerships, and potential licensing or milestone-driven deals.

Clinical Activity A robust clinical program with Phase 2/3 progression for Actimab-A and preclinical ATNM-400, along with multiple conference presentations, indicates momentum that can attract research collaborations, strategic investment, and partner-led trials.

Manufacturing IP Extensive intellectual property around cyclotron-based production of Ac-225 positions Actinium as a potential supplier or collaborator for radiopharmaceutical manufacturing, appealing to downstream manufacturers and biopharma partners.

Financial Position With a revenue range of 25-50 million and total funding of 106 million, Actinium shows a stable, investable profile suitable for strategic partnerships, co-funding opportunities, and joint ventures to accelerate development.